o NoneEntity Type
0001506251
Trail One, Inc
Trail One, Inc.
TrailOne, Inc.
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Citius Pharmaceuticals, Inc.
Jurisdiction of Incorporation/OrganizationNEVADA 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Citius Pharmaceuticals, Inc. 
Street Address 1Street Address 2
 11 COMMERCE DRIVE FIRST FLOOR
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 CRANFORD NEW JERSEY 07016 908-967-6677 



3. Related Persons
Last NameFirst NameMiddle Name
HolubiakMyron
Street Address 1Street Address 2
c/o Citius Pharmaceuticals, Inc.11 Commerce Drive, First Floor
CityState/Province/CountryZIP/Postal Code
CranfordNEW JERSEY07016
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
MazurLeonard
Street Address 1Street Address 2
c/o Citius Pharmaceuticals, Inc.11 Commerce Drive, First Floor
CityState/Province/CountryZIP/Postal Code
CranfordNEW JERSEY07016
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
DutiaSuren
Street Address 1Street Address 2
c/o Citius Pharmaceuticals, Inc.11 Commerce Drive, First Floor
CityState/Province/CountryZIP/Postal Code
CranfordNEW JERSEY07016
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
WebbCarol
Street Address 1Street Address 2
c/o Citius Pharmaceuticals, Inc.11 Commerce Drive, First Floor
CityState/Province/CountryZIP/Postal Code
CranfordNEW JERSEY07016
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
KaneWilliam
Street Address 1Street Address 2
c/o Citius Pharmaceuticals, Inc.11 Commerce Drive, First Floor
CityState/Province/CountryZIP/Postal Code
CranfordNEW JERSEY07016
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
SafirHoward
Street Address 1Street Address 2
c/o Citius Pharmaceuticals, Inc.11 Commerce Drive, First Floor
CityState/Province/CountryZIP/Postal Code
CranfordNEW JERSEY07016
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
HolukaEugene
Street Address 1Street Address 2
c/o Citius Pharmaceuticals, Inc.11 Commerce Drive, First Floor
CityState/Province/CountryZIP/Postal Code
CranfordNEW JERSEY07016
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
BartushakJaime
Street Address 1Street Address 2
c/o Citius Pharmaceuticals, Inc.11 Commerce Drive, First Floor
CityState/Province/CountryZIP/Postal Code
CranfordNEW JERSEY07016
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2021-01-27 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 H.C. Wainwright & Co., LLC 375
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
 H.C. Wainwright & Co., LLC 375
Street Address 1Street Address 2
 430 PARK AVENUE  
City State/Province/CountryZIP/Postal Code
 NEW YORK NEW YORK 10022
State(s) of Solicitation o All States o Foreign/Non-US
 NEVADA
 NEW YORK
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 20000012 USD o Indefinite
Total Amount Sold $ 20000012 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
  


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 7


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 1400000 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Citius Pharmaceuticals Charts.
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Citius Pharmaceuticals Charts.

Citius Pharmaceuticals, Inc. News

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
Wednesday 1 May 2024 (5 days ago) • PR Newswire (US)
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
Friday 26 April 2024 (1 week ago) • PR Newswire (US)
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Thursday 11 April 2024 (3 weeks ago) • PR Newswire (US)
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
Thursday 4 April 2024 (1 month ago) • PR Newswire (US)
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Monday 18 March 2024 (2 months ago) • PR Newswire (US)
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
Friday 8 March 2024 (2 months ago) • PR Newswire (US)
Form EFFECT - Notice of Effectiveness
Monday 4 March 2024 (2 months ago) • Edgar (US Regulatory)
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
Monday 26 February 2024 (2 months ago) • PR Newswire (US)
Form S-3 - Registration statement under Securities Act of 1933
Saturday 24 February 2024 (2 months ago) • Edgar (US Regulatory)
Form S-8 - Securities to be offered to employees in employee benefit plans
Saturday 24 February 2024 (2 months ago) • Edgar (US Regulatory)
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
Saturday 24 February 2024 (2 months ago) • PR Newswire (US)
Form 8-K - Current report
Friday 16 February 2024 (3 months ago) • Edgar (US Regulatory)

More Citius Pharmaceuticals, Inc. News Articles